title: Cell kinetics of head and neck cancers.
abstract: We measured the tumor cell proliferative rate in 26 patients with head and neck cancer, 22 of which were squamous cell carcinomas (SCCs). Patients received sequential infusions of iododeoxyuridine and bromodeoxyuridine, after which the tumor was biopsied and studied. The percentage of labeled cells [labeling index (LI)] in well-differentiated SCCs was 20.4 +/- 2.7% (mean +/- SE) and 23.8 +/- 2.1% in moderately differentiated SCCs (P = 0.135). The LIs of two poorly differentiated SCCs were 39.4 and 55.9%. The LI was 2.5% in a high-grade lymphoepithelioma and 24.8% in a malignant lymphoma. In one well-differentiated and one poorly differentiated mucoepidermoid tumor, the LIs were 3.0% and 29.1%, respectively. S-phase duration time measurements ranged from 5.1-21.5 h (12.8 +/- 1.5). The calculated potential doubling times ranged from 18.8-84.5 h (47.3 +/- 6.7). The duration of G2 was between 90 and 180 min. To track the fate of labeled cells, in four patients a repeat biopsy was obtained 7-14 days after the iododeoxyuridine/bromodeoxyuridine infusion. These patients did not receive treatment between the biopsies. Due to the dilution of the label, most labeled cells in the second biopsy demonstrated a "fragmented" pattern resulting from repeated cell divisions. In two patients, however, 25% of cells in the second biopsy had undiluted label, suggesting that these cells had not divided after incorporating iododeoxyuridine/bromodeoxyuridine. On Day 7 labeled cells migrated to keratinized parts of tumors and to necrotic foci. Thus, the arrest of cell cycle transition, tumor cell differentiation, and cell death may be major routes of tumor cell loss from the proliferative compartment. This may explain the difference between very short potential doubling times and the actual rate of tumor growth.
authors.affiliation: Rush Cancer Institute, Department of Pathology, Department of Otolaryngology, and Department of Radiation Oncology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612-3833, USA.
authors.forename: V M
authors.initials: VM
authors.lastname: Kotelnikov
authors.forename: I V
authors.initials: IV
authors.lastname: Coon JS
authors.forename: A
authors.initials: A
authors.lastname: Haleem
authors.forename: I V
authors.initials: IV
authors.lastname: Taylor S
authors.forename: J
authors.initials: J
authors.lastname: Hutchinson
authors.forename: W
authors.initials: W
authors.lastname: Panje
authors.forename: D D
authors.initials: DD
authors.lastname: Caldarelli
authors.forename: K
authors.initials: K
authors.lastname: Griem
authors.forename: H D
authors.initials: HD
authors.lastname: Preisler
mesh_terms: D001706:Biopsy; D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002453:Cell Cycle; D002455:Cell Division; D004273:DNA, Neoplasm / Q000096:biosynthesis; D016195:G2 Phase; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D007065:Idoxuridine; D007700:Kinetics; D008223:Lymphoma / Q000201:enzymology; D008940:Mitotic Index; D016196:S Phase; D013997:Time Factors
chemical_list: D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine; D007065:Idoxuridine